Ekaterine Arkania

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 415 citations · Full text

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki et al. · The Lancet Oncology · 2024 · 61 citations

Breast Oncology, Oncology, Clinical Trials +12

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

Mafalda Oliveira, Denys Pominchuck, Zbigniew Nowecki et al. · Cancer Research · 2023 · 59 citations

Breast Oncology, Multi-dose Phase 2, Gynecology +17

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Caicun Zhou, Yanping Hu, Ekaterine Arkania et al. · Cancer Cell · 2024 · 47 citations

Medicine, Metronomic Therapy, Pathology +7

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy

Lee S. Schwartzberg, Rudolph M. Navari, Rebecca Clark-Snow et al. · The Oncologist · 2019 · 32 citations · Full text